Background Treatment options for patients with ankylosing spondylitis are few. We aimed to
assess the effectiveness of infliximab, an antibody to tumour necrosis factor (TNF)-α, in …

Objective To introduce a new standardized ultrasound score based on 7 joints of the clinically
dominant hand and foot (German US7 score) implemented in daily rheumatologic practice…

Objective There is increasing evidence that tumor necrosis factor α (TNFα) is centrally
involved in the pathogenesis of ankylosing spondylitis (AS) and other spondylarthritides. This …

Background The Danish National Patient Registry (DNPR) is one of the world’s oldest
nationwide hospital registries and is used extensively for research. Many studies have validated …

The methodological advances in epidemiology have facilitated the use of the Danish Civil
Registration System (CRS) in ways not previously described systematically. We reviewed the …

Preparations enriched by a specific protein are rarely easily obtained from natural host cells.
Hence, recombinant protein production is frequently the sole applicable procedure. The …

Objective Treatment of ankylosing spondylitis (AS) with infliximab, an anti–tumor necrosis
factor α monoclonal antibody, was shown to be efficacious in patients with active disease …

… Furthermore, we believe that the NH group of the imidazole moiety is important for the
enantioselectivity. Hitherto we have not been able to demonstrate any enhancement of …

Introduction Evidence from a number of open-label, uncontrolled studies has suggested that
rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-…

Objective To examine the long‐term outcome of patients with active ankylosing spondylitis (AS)
clinically and by magnetic resonance imaging (MRI) after continuous treatment with the …